Scalable, methanol‐free manufacturing of the SARS‐CoV‐2 receptor‐binding domain in engineered Komagataella phaffii

Mostrar otras versiones (1)

Prevention of COVID‐19 on a global scale will require the continued development of high‐volume, low‐cost platforms for the manufacturing of vaccines to supply ongoing demand. Vaccine candidates based on recombinant protein subunits remain important because they can be manufactured at low costs in ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalvie, Neil C., Biedermann, Andrew M., Rodriguez‐Aponte, Sergio A., Naranjo, Christopher A., Rao, Harish D., Rajurkar, Meghraj P., Lothe, Rakesh R., Shaligram, Umesh S., Johnston, Ryan S., Crowell, Laura E., Castelino, Seraphin, Tracey, Mary K., Whittaker, Charles A., Love, J. Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653030/
https://www.ncbi.nlm.nih.gov/pubmed/34780057
http://dx.doi.org/10.1002/bit.27979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653030/
https://www.ncbi.nlm.nih.gov/pubmed/34780057
http://dx.doi.org/10.1002/bit.27979

Ejemplares similares